Rallybio announces annual stockholder meeting
RLYB•Rallybio will hold its annual stockholder meeting on November 4, 2026, to vote on its merger with Avenzo Therapeutics and a special cash distribution estimated at $82.7 million, or $13.56 per share. The merger is expected to close around November 6, subject to shareholder approval and other closing conditions.
1. Meeting and merger vote
Rallybio will hold its annual stockholder meeting on November 4, 2026, to vote on its merger with Avenzo Therapeutics. Shareholder approval is required for a special cash distribution estimated at $82.7 million, or $13.56 per share. The merger is expected to close around November 6, subject to shareholder approval and other closing conditions.
